Shares of SoftOx Solutions cratered 14.6% to NOK 0.11 on September 23 after the Norwegian biotech's half-year report revealed a NOK 13.6 million loss, deepening investor anxiety over a company that has yet to generate meaningful revenue from its disinfection and wound-care technology. SoftOx Solutions Bleeds NOK 13.6 Million in Six Months — Is This Clinical-Stage Bet Running Out of Time and Cash?
Shares plunged 14.6% to NOK 0.11 on September 23 after SoftOx Solutions, a tiny Oslo-listed biotech developing inhaled treatments for lung infections, reported a first-half loss of NOK 13.6 million — a sharp deterioration from the company's recent trajectory. The sell-off was company-specific; the broader biotech sector traded higher on the day. For shareholders of a company with a market cap under US$10 million , the question is brutally simple: can SoftOx reach a meaningful milestone before the money runs out?
The Loss Is Accelerating, Not Shrinking
In Q1 alone, SoftOx posted a pre-tax loss of NOK 5.1 million, compared with a NOK 1.9 million profit in Q1 2025. A half-year loss of NOK 13.6 million implies the second quarter was even worse, around NOK 8.5 million in red ink. The reversal wipes out the narrative that Q4 2025's "sharpened clinical focus and cost control" and Q3 2025's narrowing losses had put the company on a sustainable path. R&D costs consumed 74% of operating expenses in Q1 , and clinical spending is only intensifying.
The Cash Runway Is Dangerously Short
The company has less than one year of cash runway based on its free cash flow trend, which Simply Wall St flags as a "major risk." As of Q1-end, cash stood at NOK 19.6 million — but at the half-year burn rate of NOK 13.6 million, that cushion could evaporate by early 2027 without fresh capital. SoftOx has already been tapping a financing facility with investment fund Long State Investments through repeated private placements , diluting its now ~2.5 billion outstanding shares. More dilution looks inevitable.
Clinical Milestones Are the Only Lifeline
The company reported positive safety data from a dose-escalation phase for its lead inhaled anti-infective program, with no serious adverse events observed. A proof-of-concept study in cystic fibrosis patients is expected in the first half of 2027 , and a separate biodefense program began Phase 1 dosing in June 2026 backed by European Defence Fund partners . Positive data could attract a pharma partner, but that timeline sits beyond the current cash horizon.
Micro-Cap Reality Check With revenue under US$5 million , just two employees , and a stock trading near its 52-week low of NOK 0.05 , SoftOx is a textbook binary outcome: either clinical results unlock a partnership and a capital raise at better terms, or the company dilutes itself into irrelevance. Today's report made the latter scenario feel closer.